{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-002669","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.583701+00:00","generated_at":"2026-05-23T01:36:39.553422+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"BioCryst appoints Steve Frank to board; board size increased to 11","bullets":["Steven Frank elected to board effective May 2, 2025, filling new seat after board expansion from 10 to 11 directors.","Frank is chairman of global healthcare investment banking at J.P. Morgan; previously at Bear Stearns.","Initial equity grant of $500,000 (60% options, 40% RSUs), prorated from effective date to 2025 annual meeting.","Frank brings healthcare M&A and capital allocation expertise as BioCryst approaches profitability.","Frank's term expires at 2027 annual meeting; no committee assignments initially."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-002669","json":"https://secwatch.observer/filing/0001171843-25-002669.json","markdown":"https://secwatch.observer/filing/0001171843-25-002669.md","text":"https://secwatch.observer/filing/0001171843-25-002669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184325002669/0001171843-25-002669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184325002669/f8k_050125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T01:36:39.553422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b4dd61df7","claim":"Steven Frank was elected as Director at BIOCRYST PHARMACEUTICALS INC.","evidence_excerpt":"On April 30, 2025, the Board of Directors (the “Board”) of BioCryst Pharmaceuticals, Inc. (the “Company”) approved an increase in the size of the Board from ten to eleven directors and elected Steven Frank to fill the vacancy created by the enlargement of the Board, effective May 2, 2025 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184325002669/0001171843-25-002669-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}